Profund Advisors LLC Has $958,000 Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Profund Advisors LLC lessened its position in Twist Bioscience Co. (NASDAQ:TWST) by 49.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 19,450 shares of the company’s stock after selling 18,780 shares during the period. Profund Advisors LLC’s holdings in Twist Bioscience were worth $958,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of TWST. Artisan Partners Limited Partnership grew its position in Twist Bioscience by 111.3% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after purchasing an additional 1,961,621 shares during the period. Victory Capital Management Inc. increased its position in shares of Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after acquiring an additional 300,891 shares in the last quarter. Norges Bank acquired a new stake in shares of Twist Bioscience in the 4th quarter worth about $10,766,000. Dimensional Fund Advisors LP lifted its position in Twist Bioscience by 29.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock valued at $46,732,000 after acquiring an additional 284,884 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its stake in Twist Bioscience by 74.6% during the 2nd quarter. Ensign Peak Advisors Inc now owns 331,373 shares of the company’s stock valued at $16,330,000 after purchasing an additional 141,557 shares during the last quarter.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 5,139 shares of Twist Bioscience stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the completion of the transaction, the chief executive officer now owns 499,593 shares of the company’s stock, valued at approximately $19,948,748.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Emily M. Leproust sold 5,139 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the completion of the sale, the chief executive officer now owns 499,593 shares of the company’s stock, valued at $19,948,748.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Paula Green sold 1,137 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the transaction, the senior vice president now owns 88,837 shares of the company’s stock, valued at $3,547,261.41. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,125 shares of company stock worth $664,784. 3.92% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Robert W. Baird increased their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Guggenheim assumed coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective on the stock. Barclays lowered their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Finally, TD Cowen increased their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $48.22.

Twist Bioscience Stock Down 2.5 %

NASDAQ TWST opened at $45.29 on Tuesday. The company has a market cap of $2.64 billion, a PE ratio of -13.48 and a beta of 1.76. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90. The firm’s 50-day simple moving average is $47.05 and its two-hundred day simple moving average is $43.14.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same period last year, the business posted ($1.01) earnings per share. The firm’s quarterly revenue was up 27.7% on a year-over-year basis. As a group, equities research analysts anticipate that Twist Bioscience Co. will post -3.13 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.